Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Fortrea Holdings Inc. Banner

Fortrea Holdings Inc.

FTRE Stock Analysis

Page title

Section title

About Fortrea Holdings Inc.

Biotechnology
Healthcare

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services...

Fortrea Holdings Inc. Key Metrics

Market Cap
$2B
52 Weeks Low
$18.07
52 Weeks High
$41.02
P/B
1.46x
P/E
-8.03x
P/S
0.74x

Upcoming Events

    FTRE Analyst Forecasts



    FTRE Financials

    FTRE Income Statement Key Metrics

    • Revenue(TTM)2.88 B
    • Gross Profit(TTM)472.40 M
    • EBITDA(TTM)48.50 M
    • Net Income(TTM)-265.30 M
    • EPS Diluted(TTM)-2.98

    Decode FTRE's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    FTRE earnings and revenue history

    FTRE Return on Equity

    See how efficiently FTRE generates profit for it's shareholders.

    0%

    10
    0
    100
    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    FTRE's Return on Equity has shown poor growth over the past 10 years, increasing by only -63.50%.

    FTRE Revenue Growth

    See how FTRE has grown it's revenue over the past 10 years.


    Revenue Growth

    FTRE's revenue has shown poor growth over the past 10 years, increasing by only 4.77%.